Information Governance Department

Suite 9 Buckingham Row Brick Kiln Lane Wigan WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2025/11219

Date Received: 10th November 2025

Response Due: 8<sup>th</sup> December 2025

Date: 17th November 2025

## Dear Sir/Madam

With reference to your request for information received on 10<sup>th</sup> November 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do not hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

 Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand).
The Trust does not treat Haemophilia patients.

I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column:

July through September 2025	Age											
	0-12	years	<b>;</b>				13+					
Brand name (scientific)	Mild Moderate		erate	Severe		Mild		Moderate		Severe		
	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD
Hemlibra (emicizumab)												
Altuvoct (giroctocogene fitelparvovec)												
Esperoct (turoctocog alfa pegol)												
Elocta (efmoroctocog alfa)												

Advate (octocog alfa)						
Kovaltry (octocog alfa)						
Iblias (octocog alfa)						
Refacto AF (moroctocog alfa)						
Xyntha (moroctocog alfa)						
NovoEight (turoctocog alfa)						
Nuwiq (simoctocog alfa)		·				
Vihuma (simoctocog alfa)						

## Inhibitor patients

2. For Hemlibra-treated Hemophilia A Inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

The Trust does not treat Haemophilia patients.

Age group (Hemophilia A inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

## Non-inhibitor patients

3. For Hemlibra-treated Hemophilia A non-inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

The Trust does not treat Haemophilia patients.

Age group (Hemophilia A non-inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

Gary Masterman

Associate Director of Pharmacy (Governance Assurance)

## PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111